Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity
作者:Amit Nathubhai、Teemu Haikarainen、Jarkko Koivunen、Sudarshan Murthy、Françoise Koumanov、Matthew D. Lloyd、Geoffrey D. Holman、Taina Pihlajaniemi、David Tosh、Lari Lehtiö、Michael D. Threadgill
DOI:10.1021/acs.jmedchem.6b01574
日期:2017.1.26
Compounds 13 and 14 were evaluated against 11 PARP isoforms to reveal that both 13 and 14 were more potent and isoform selective toward inhibiting tankyrases (TNKSs) than the "standard" inhibitor 1 (XAV939)(5), i.e., IC50 = 100 pM vs TNKS2 and IC50 = 6.5 mu M vs PARP1 for 14. In cellular assays, 13 and 14 inhibited Wnt-signaling, enhanced insulin-stimulated glucose uptake, and inhibited the proliferation of DLD-1 colorectal adenocarcinoma cells to a greater extent than 1.
[EN] TANKYRASE INHIBITORS<br/>[FR] INHIBITEURS DE TANKYRASE
申请人:UNIV BATH
公开号:WO2018046933A1
公开(公告)日:2018-03-15
The invention relates to compounds of formula (I): (I) and salts, solvates, tautomers and stereoisomers thereof, where the definitions of the variables are provided herein. The invention also relates to pharmaceutical compositions comprising compounds of formula (I) as well as for the use of such compounds as tankyrase inhibitors and for the treatment of diseases such as cancer.